What is Leerink Partnrs' Forecast for MREO Q1 Earnings?

Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Mereo BioPharma Group in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst J. Schwartz anticipates that the company will post earnings per share of $0.00 for the quarter. Leerink Partnrs also issued estimates for Mereo BioPharma Group's Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2026 earnings at $0.00 EPS.

A number of other equities analysts have also weighed in on MREO. Needham & Company LLC reiterated a "buy" rating and set a $7.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Tuesday, October 1st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $7.50.

Mereo BioPharma Group Stock Up 1.1 %

Shares of MREO stock traded up $0.04 on Wednesday, hitting $3.53. 385,190 shares of the stock were exchanged, compared to its average volume of 799,464. Mereo BioPharma Group has a one year low of $3.17 and a one year high of $5.02. The firm's 50 day moving average is $4.20 and its two-hundred day moving average is $3.95.

Hedge Funds Weigh In On Mereo BioPharma Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP grew its position in Mereo BioPharma Group by 12.9% in the second quarter. Rubric Capital Management LP now owns 15,307,347 shares of the company's stock worth $55,106,000 after acquiring an additional 1,754,350 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Mereo BioPharma Group by 56.7% in the 3rd quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company's stock worth $50,865,000 after purchasing an additional 4,464,984 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new position in shares of Mereo BioPharma Group during the 2nd quarter valued at about $24,158,000. Frazier Life Sciences Management L.P. raised its holdings in shares of Mereo BioPharma Group by 15.8% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company's stock valued at $20,952,000 after buying an additional 696,408 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Mereo BioPharma Group by 46.9% in the 2nd quarter. Millennium Management LLC now owns 3,201,705 shares of the company's stock worth $11,526,000 after buying an additional 1,022,570 shares during the last quarter. Hedge funds and other institutional investors own 62.83% of the company's stock.

Insider Activity

In other news, CFO Christine Ann Fox sold 9,128 shares of the business's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $4.47, for a total transaction of $40,802.16. Following the completion of the transaction, the chief financial officer now owns 108,443 shares of the company's stock, valued at approximately $484,740.21. The trade was a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Charles Sermon sold 9,980 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total transaction of $44,610.60. Following the completion of the transaction, the general counsel now owns 240,007 shares in the company, valued at approximately $1,072,831.29. This trade represents a 3.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 158,175 shares of company stock worth $702,832 over the last ninety days.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.